25 XP   0   0   10

Lantern Pharma Inc
Buy, Hold or Sell?

Let's analyze Lantern Pharma Inc together

I guess you are interested in Lantern Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lantern Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lantern Pharma Inc

I send you an email if I find something interesting about Lantern Pharma Inc.

Quick analysis of Lantern Pharma Inc (30 sec.)










What can you expect buying and holding a share of Lantern Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.32
Expected worth in 1 year
$1.81
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$-1.52
Return On Investment
-35.4%

For what price can you sell your share?

Current Price per Share
$4.29
Expected price per share
$3.83 - $7.21
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Lantern Pharma Inc (5 min.)




Live pricePrice per Share (EOD)

$4.29

Intrinsic Value Per Share

$-12.90 - $-15.02

Total Value Per Share

$-9.58 - $-11.70

2. Growth of Lantern Pharma Inc (5 min.)




Is Lantern Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$35.7m$57.1m-$14.5m-34.3%

How much money is Lantern Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4.3m-$3.3m-$1m-23.8%
Net Profit Margin-400.9%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Lantern Pharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#477 / 966

Most Revenue
#692 / 966

Most Profit
#396 / 966

Most Efficient
#631 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Lantern Pharma Inc? (5 min.)

Welcome investor! Lantern Pharma Inc's management wants to use your money to grow the business. In return you get a share of Lantern Pharma Inc.

What can you expect buying and holding a share of Lantern Pharma Inc?

First you should know what it really means to hold a share of Lantern Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Lantern Pharma Inc is $4.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lantern Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lantern Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.32. Based on the TTM, the Book Value Change Per Share is $-0.38 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lantern Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.51-11.8%-0.41-9.4%-0.32-7.5%-0.29-6.7%-0.29-6.7%
Usd Book Value Change Per Share-0.46-10.8%-0.38-8.8%-0.29-6.8%0.184.3%0.184.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.46-10.8%-0.38-8.8%-0.29-6.8%0.184.3%0.184.3%
Usd Price Per Share8.80-5.53-5.34-8.52-8.52-
Price to Earnings Ratio-4.35--3.32--4.35--9.75--9.75-
Price-to-Total Gains Ratio-19.00--14.25--19.18--28.73--28.73-
Price to Book Ratio2.65-1.47-1.01-2.46-2.46-
Price-to-Total Gains Ratio-19.00--14.25--19.18--28.73--28.73-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.29
Number of shares233
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.380.18
Usd Total Gains Per Share-0.380.18
Gains per Quarter (233 shares)-88.4443.03
Gains per Year (233 shares)-353.75172.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-354-3640172162
20-708-7180344334
30-1061-10720516506
40-1415-14260688678
50-1769-17800861850
60-2123-2134010331022
70-2476-2488012051194
80-2830-2842013771366
90-3184-3196015491538
100-3538-3550017211710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.018.00.00.0%0.018.00.00.0%0.018.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%3.015.00.016.7%3.015.00.016.7%3.015.00.016.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%3.015.00.016.7%3.015.00.016.7%3.015.00.016.7%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Lantern Pharma Inc

About Lantern Pharma Inc

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Fundamental data was last updated by Penke on 2024-06-18 02:50:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Lantern Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lantern Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lantern Pharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lantern Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-400.9%+400.9%
TTM-400.9%YOY--400.9%
TTM-400.9%5Y-89.1%-311.8%
5Y-89.1%10Y-89.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.0%+168.0%
TTM-400.9%-209.9%-191.0%
YOY--242.3%+242.3%
5Y-89.1%-401.7%+312.6%
10Y-89.1%-532.2%+443.1%
1.1.2. Return on Assets

Shows how efficient Lantern Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lantern Pharma Inc to the Biotechnology industry mean.
  • -13.7% Return on Assets means that Lantern Pharma Inc generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lantern Pharma Inc:

  • The MRQ is -13.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.7%TTM-9.8%-3.9%
TTM-9.8%YOY-5.5%-4.3%
TTM-9.8%5Y-11.2%+1.4%
5Y-11.2%10Y-11.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.7%-11.9%-1.8%
TTM-9.8%-11.9%+2.1%
YOY-5.5%-11.3%+5.8%
5Y-11.2%-13.5%+2.3%
10Y-11.2%-14.9%+3.7%
1.1.3. Return on Equity

Shows how efficient Lantern Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lantern Pharma Inc to the Biotechnology industry mean.
  • -15.2% Return on Equity means Lantern Pharma Inc generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lantern Pharma Inc:

  • The MRQ is -15.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.2%TTM-10.6%-4.7%
TTM-10.6%YOY-5.8%-4.7%
TTM-10.6%5Y-15.3%+4.7%
5Y-15.3%10Y-15.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.2%-14.2%-1.0%
TTM-10.6%-15.7%+5.1%
YOY-5.8%-14.3%+8.5%
5Y-15.3%-19.2%+3.9%
10Y-15.3%-19.7%+4.4%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Lantern Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lantern Pharma Inc is operating .

  • Measures how much profit Lantern Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lantern Pharma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lantern Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-467.1%+467.1%
TTM-467.1%YOY--467.1%
TTM-467.1%5Y-103.8%-363.3%
5Y-103.8%10Y-103.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--354.6%+354.6%
TTM-467.1%-225.9%-241.2%
YOY--252.2%+252.2%
5Y-103.8%-428.3%+324.5%
10Y-103.8%-531.1%+427.3%
1.2.2. Operating Ratio

Measures how efficient Lantern Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lantern Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.671-4.671
TTM4.671YOY-+4.671
TTM4.6715Y1.038+3.633
5Y1.03810Y1.0380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM4.6713.332+1.339
YOY-3.502-3.502
5Y1.0385.271-4.233
10Y1.0386.915-5.877
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Lantern Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lantern Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.98 means the company has $9.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lantern Pharma Inc:

  • The MRQ is 9.984. The company is very able to pay all its short-term debts. +2
  • The TTM is 16.035. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.984TTM16.035-6.051
TTM16.035YOY18.218-2.184
TTM16.0355Y25.957-9.923
5Y25.95710Y25.9570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9843.767+6.217
TTM16.0354.000+12.035
YOY18.2184.905+13.313
5Y25.9575.883+20.074
10Y25.9576.286+19.671
1.3.2. Quick Ratio

Measures if Lantern Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lantern Pharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 14.76 means the company can pay off $14.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lantern Pharma Inc:

  • The MRQ is 14.761. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 22.158. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.761TTM22.158-7.397
TTM22.158YOY22.850-0.692
TTM22.1585Y29.538-7.380
5Y29.53810Y29.5380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.7613.054+11.707
TTM22.1583.506+18.652
YOY22.8504.756+18.094
5Y29.5385.757+23.781
10Y29.5386.338+23.200
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Lantern Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lantern Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lantern Pharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Lantern Pharma Inc assets are financed with 10.0% credit (debt) and the remaining percentage (100% - 10.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lantern Pharma Inc:

  • The MRQ is 0.100. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.068. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.100TTM0.068+0.031
TTM0.068YOY0.058+0.011
TTM0.0685Y0.091-0.023
5Y0.09110Y0.0910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1000.330-0.230
TTM0.0680.342-0.274
YOY0.0580.287-0.229
5Y0.0910.368-0.277
10Y0.0910.382-0.291
1.4.2. Debt to Equity Ratio

Measures if Lantern Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lantern Pharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.1% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lantern Pharma Inc:

  • The MRQ is 0.111. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.074. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.111TTM0.074+0.037
TTM0.074YOY0.061+0.012
TTM0.0745Y0.129-0.055
5Y0.12910Y0.1290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1110.365-0.254
TTM0.0740.415-0.341
YOY0.0610.370-0.309
5Y0.1290.443-0.314
10Y0.1290.476-0.347
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Lantern Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lantern Pharma Inc generates.

  • Above 15 is considered overpriced but always compare Lantern Pharma Inc to the Biotechnology industry mean.
  • A PE ratio of -4.35 means the investor is paying $-4.35 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lantern Pharma Inc:

  • The EOD is -2.121. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.350. Based on the earnings, the company is expensive. -2
  • The TTM is -3.316. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.121MRQ-4.350+2.230
MRQ-4.350TTM-3.316-1.034
TTM-3.316YOY-4.350+1.034
TTM-3.3165Y-9.753+6.437
5Y-9.75310Y-9.7530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.121-2.341+0.220
MRQ-4.350-2.997-1.353
TTM-3.316-2.882-0.434
YOY-4.350-3.553-0.797
5Y-9.753-6.262-3.491
10Y-9.753-6.288-3.465
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lantern Pharma Inc:

  • The EOD is -3.758. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.708. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.484. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.758MRQ-7.708+3.950
MRQ-7.708TTM-4.484-3.224
TTM-4.484YOY-4.610+0.125
TTM-4.4845Y-12.570+8.086
5Y-12.57010Y-12.5700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.758-2.932-0.826
MRQ-7.708-3.739-3.969
TTM-4.484-3.776-0.708
YOY-4.610-4.917+0.307
5Y-12.570-7.942-4.628
10Y-12.570-8.503-4.067
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lantern Pharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.65 means the investor is paying $2.65 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lantern Pharma Inc:

  • The EOD is 1.291. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.647. Based on the equity, the company is underpriced. +1
  • The TTM is 1.465. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.291MRQ2.647-1.357
MRQ2.647TTM1.465+1.182
TTM1.465YOY1.014+0.451
TTM1.4655Y2.458-0.992
5Y2.45810Y2.4580.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2911.843-0.552
MRQ2.6472.249+0.398
TTM1.4652.301-0.836
YOY1.0142.412-1.398
5Y2.4583.782-1.324
10Y2.4584.212-1.754
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lantern Pharma Inc.

3.1. Institutions holding Lantern Pharma Inc

Institutions are holding 22.163% of the shares of Lantern Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Vanguard Group Inc3.38070.0001363720-1614-0.4418
2024-03-31Goss Wealth Management LLC1.49210.0123160532-5440-3.2777
2024-03-31Geode Capital Management, LLC0.81210.000187374-7662-8.0622
2024-03-31CM Management, LLC0.60420.480465000-15000-18.75
2023-12-31Renaissance Technologies Corp0.40710.000343800570014.9606
2024-03-31Redmond Asset Management, LLC0.37610.113140462-200-0.4919
2024-03-31Horizon Asset Management Inc/ny0.26760.00482879100
2024-03-31Bank of New York Mellon Corp0.246102648210.0038
2024-03-31Susquehanna International Group, LLP0.2397025784257840
2024-03-31UBS Group AG0.2370.000125500-458-1.7644
2024-03-31State Street Corporation0.2329025052-2700-9.729
2024-03-31Pathway Financial Advisors LLC0.23240.059525001-3500-12.2803
2023-12-31Meridian Wealth Management, LLC0.18270.005419660300018.0072
2024-03-31BlackRock Inc0.1827019659-303-1.5179
2024-03-31Tocqueville Asset Management L.P.0.17660.002719000190000
2024-03-31Northern Trust Corp0.11920128232301.8264
2024-03-31Raymond James Finl Svs Advisors, Inc.0.11160.000212004120040
2023-12-31Sigma Planning Corp0.11040.00411875-6250-34.4828
2024-03-31Dimensional Fund Advisors, Inc.0.109901182800
2024-03-31Honkamp Krueger Financial Services Inc0.10820.003311640116400
Total 9.62930.68631035987+34232+3.3%

3.2. Funds holding Lantern Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Vanguard Total Stock Mkt Idx Inv2.38050.000125611300
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr0.92260.00059926500
2024-04-30Fidelity Extended Market Index0.40250.000643307-392-0.897
2024-05-31Horizon Kinetics Medical ETF0.26761.02882879100
2024-04-30Fidelity Total Market Index0.21420.00012304600
2024-04-30Incrementum All Seasons Fund CHF I0.17560.05381888800
2024-05-30iShares Micro-Cap ETF0.13740.011114786-206-1.3741
2024-04-30Fidelity Series Total Market Index0.07930.0001853300
2024-04-30Fidelity Nasdaq Composite Index0.06360.0002683800
2024-03-31NT Ext Equity Mkt Idx Fd - NL0.06020.0009647900
2023-12-31SSgA U.S. Extended Market Index Class I0.05860.001630000
2024-03-31Vanguard Instl Ttl Stck Mkt Idx Tr0.05560.0002598700
2024-04-30Vanguard Instl Ttl Stk Mkt Idx InstlPls0.05560.0001598700
2024-03-31NT Ext Equity Mkt Idx Fd - L0.05440.0008585700
2024-03-31Northern Trust Extended Eq Market Idx0.05440.0008585700
2024-04-30DFA US Core Equity 2 I0.05070.0001545400
2024-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04840.0009520630.0577
2024-05-31Avantis US Small Cap Equity ETF0.04090.0026439900
2024-05-31State St US Extended Mkt Indx NL Cl C0.03350.0012360000
2024-04-30Spartan Total Market Index Pool E0.02870.0001309100
Total 5.18431.104557784-595-0.1%

3.3. Insider Transactions

Insiders are holding 14.753% of the shares of Lantern Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-05-23Aaron G.l. FletcherSELL100006.25
2024-02-28Aaron G.l. FletcherSELL742974.85
2024-01-17Aaron G.l. FletcherSELL588894.2
2023-11-29Leslie W KreisSELL1453483.44
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Lantern Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.463-0.380-18%-0.291-37%0.185-351%0.185-351%
Book Value Per Share--3.3243.935-16%5.272-37%4.269-22%4.269-22%
Current Ratio--9.98416.035-38%18.218-45%25.957-62%25.957-62%
Debt To Asset Ratio--0.1000.068+46%0.058+73%0.091+10%0.091+10%
Debt To Equity Ratio--0.1110.074+50%0.061+81%0.129-14%0.129-14%
Dividend Per Share----0%-0%-0%-0%
Eps---0.506-0.405-20%-0.323-36%-0.288-43%-0.288-43%
Free Cash Flow Per Share---0.285-0.316+11%-0.305+7%-0.241-16%-0.241-16%
Free Cash Flow To Equity Per Share---0.280-0.342+22%-50.561+17936%-10.954+3808%-10.954+3808%
Gross Profit Margin--1.0011.0030%1.000+0%1.001+0%1.001+0%
Intrinsic Value_10Y_max---15.024--------
Intrinsic Value_10Y_min---12.900--------
Intrinsic Value_1Y_max---1.230--------
Intrinsic Value_1Y_min---1.208--------
Intrinsic Value_3Y_max---3.906--------
Intrinsic Value_3Y_min---3.725--------
Intrinsic Value_5Y_max---6.835--------
Intrinsic Value_5Y_min---6.326--------
Market Cap46155252.000-105%94677440.00059790747.005+58%57917654.203+63%92654343.068+2%92654343.068+2%
Net Profit Margin----4.0090%-0%-0.8910%-0.8910%
Operating Margin----4.6710%-0%-1.0380%-1.0380%
Operating Ratio---4.671-100%-0%1.038-100%1.038-100%
Pb Ratio1.291-105%2.6471.465+81%1.014+161%2.458+8%2.458+8%
Pe Ratio-2.121+51%-4.350-3.316-24%-4.3500%-9.753+124%-9.753+124%
Price Per Share4.290-105%8.8005.533+59%5.340+65%8.518+3%8.518+3%
Price To Free Cash Flow Ratio-3.758+51%-7.708-4.484-42%-4.610-40%-12.570+63%-12.570+63%
Price To Total Gains Ratio-9.263+51%-19.000-14.253-25%-19.175+1%-28.733+51%-28.733+51%
Quick Ratio--14.76122.158-33%22.850-35%29.538-50%29.538-50%
Return On Assets---0.137-0.098-29%-0.055-60%-0.112-18%-0.112-18%
Return On Equity---0.152-0.106-31%-0.058-62%-0.153+0%-0.153+0%
Total Gains Per Share---0.463-0.380-18%-0.291-37%0.185-351%0.185-351%
Usd Book Value--35765217.00042586040.250-16%57178603.500-37%46610841.222-23%46610841.222-23%
Usd Book Value Change Per Share---0.463-0.380-18%-0.291-37%0.185-351%0.185-351%
Usd Book Value Per Share--3.3243.935-16%5.272-37%4.269-22%4.269-22%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.506-0.405-20%-0.323-36%-0.288-43%-0.288-43%
Usd Free Cash Flow---3070740.000-3417497.500+11%-3308409.500+8%-2621955.500-15%-2621955.500-15%
Usd Free Cash Flow Per Share---0.285-0.316+11%-0.305+7%-0.241-16%-0.241-16%
Usd Free Cash Flow To Equity Per Share---0.280-0.342+22%-50.561+17936%-10.954+3808%-10.954+3808%
Usd Market Cap46155252.000-105%94677440.00059790747.005+58%57917654.203+63%92654343.068+2%92654343.068+2%
Usd Price Per Share4.290-105%8.8005.533+59%5.340+65%8.518+3%8.518+3%
Usd Profit---5440810.000-4383644.500-19%-3339812.500-39%-3000964.722-45%-3000964.722-45%
Usd Revenue---65263.000-100%-0%14502.889-100%14502.889-100%
Usd Total Gains Per Share---0.463-0.380-18%-0.291-37%0.185-351%0.185-351%
 EOD+3 -5MRQTTM+11 -21YOY+12 -185Y+10 -2210Y+10 -22

4.2. Fundamental Score

Let's check the fundamental score of Lantern Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.121
Price to Book Ratio (EOD)Between0-11.291
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than114.761
Current Ratio (MRQ)Greater than19.984
Debt to Asset Ratio (MRQ)Less than10.100
Debt to Equity Ratio (MRQ)Less than10.111
Return on Equity (MRQ)Greater than0.15-0.152
Return on Assets (MRQ)Greater than0.05-0.137
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Lantern Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.130
Ma 20Greater thanMa 504.888
Ma 50Greater thanMa 1005.573
Ma 100Greater thanMa 2006.063
OpenGreater thanClose4.380
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-03-312023-06-302023-09-302023-12-312024-03-31
Accumulated Other Comprehensive Income  -30038-262123-13931-1071092



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets39,734
Total Liabilities3,969
Total Stockholder Equity35,765
 As reported
Total Liabilities 3,969
Total Stockholder Equity+ 35,765
Total Assets = 39,734

Assets

Total Assets39,734
Total Current Assets39,471
Long-term Assets263
Total Current Assets
Cash And Cash Equivalents 18,358
Short-term Investments 20,000
Other Current Assets 1,113
Total Current Assets  (as reported)39,471
Total Current Assets  (calculated)39,471
+/-0
Long-term Assets
Property Plant Equipment 237
Long-term Assets Other 26
Long-term Assets  (as reported)263
Long-term Assets  (calculated)263
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,953
Long-term Liabilities16
Total Stockholder Equity35,765
Total Current Liabilities
Short-term Debt 178
Accounts payable 3,775
Other Current Liabilities 3,775
Total Current Liabilities  (as reported)3,953
Total Current Liabilities  (calculated)7,729
+/- 3,775
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt16
Long-term Liabilities  (as reported)16
Long-term Liabilities  (calculated)16
+/- 0
Total Stockholder Equity
Common Stock1
Retained Earnings -60,685
Accumulated Other Comprehensive Income 2
Other Stockholders Equity 96,447
Total Stockholder Equity (as reported)35,765
Total Stockholder Equity (calculated)35,765
+/-0
Other
Capital Stock1
Cash and Short Term Investments 38,358
Common Stock Shares Outstanding 10,743
Current Deferred Revenue-3,775
Liabilities and Stockholders Equity 39,734
Net Debt -18,164
Net Invested Capital 35,765
Net Working Capital 35,517
Property Plant and Equipment Gross 237
Short Long Term Debt Total 194



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
1,433
1,038
25,613
22,493
20,360
82,505
82,432
77,606
73,950
68,403
66,380
62,164
58,836
55,509
51,426
47,772
43,648
39,734
39,73443,64847,77251,42655,50958,83662,16466,38068,40373,95077,60682,43282,50520,36022,49325,6131,0381,433000
   > Total Current Assets 
0
0
0
1,233
766
25,598
22,475
20,237
82,484
82,131
76,337
72,716
67,663
65,663
62,020
58,723
55,168
51,042
47,426
43,341
39,471
39,47143,34147,42651,04255,16858,72362,02065,66367,66372,71676,33782,13182,48420,23722,47525,5987661,233000
       Cash And Cash Equivalents 
0
0
0
1,232
634
23,798
20,803
19,229
81,374
61,354
54,669
51,524
46,652
43,363
39,258
37,202
32,479
28,423
25,572
21,938
18,358
18,35821,93825,57228,42332,47937,20239,25843,36346,65251,52454,66961,35481,37419,22920,80323,7986341,232000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
18,235
19,164
19,201
18,565
18,787
18,569
17,994
19,061
19,526
19,354
19,365
20,000
20,00019,36519,35419,52619,06117,99418,56918,78718,56519,20119,16418,235000000000
       Net Receivables 
0
0
0
0
0
0
6
0
0
76
71
181
228
339
305
592
0
0
0
860
0
08600005923053392281817176006000000
       Other Current Assets 
0
0
0
1
132
1,729
1,673
1,008
1,111
2,542
2,504
1,991
2,447
3,513
4,193
3,527
3,086
2,552
2,500
1,179
1,113
1,1131,1792,5002,5523,0863,5274,1933,5132,4471,9912,5042,5421,1111,0081,6731,7291321000
   > Long-term Assets 
0
0
0
200
272
15
18
123
20
301
1,270
1,234
739
717
145
114
342
384
346
306
263
2633063463843421141457177391,2341,270301201231815272200000
       Property Plant Equipment 
0
0
0
9
8
15
18
22
20
283
252
216
180
158
127
96
309
358
320
280
237
237280320358309961271581802162522832022181589000
       Other Assets 
0
0
0
0
263
0
0
101
0
18
1,018
1,018
559
559
0
18
0
26
0
0
0
0002601805595591,0181,018180101002630000
> Total Liabilities 
0
0
0
489
502
2,385
923
661
773
2,819
1,878
2,379
3,087
5,304
3,139
2,798
2,934
3,167
2,360
2,740
3,969
3,9692,7402,3603,1672,9342,7983,1395,3043,0872,3791,8782,8197736619232,385502489000
   > Total Current Liabilities 
0
0
0
489
502
2,277
815
552
665
2,688
1,786
2,326
3,074
5,304
3,139
2,798
2,793
3,016
2,253
2,678
3,953
3,9532,6782,2533,0162,7932,7983,1395,3043,0742,3261,7862,6886655528152,277502489000
       Short-term Debt 
0
0
0
0
53
103
0
103
103
146
149
152
155
131
92
53
120
163
168
173
178
17817316816312053921311551521491461031030103530000
       Short Long Term Debt 
0
0
0
0
53
103
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000103530000
       Accounts payable 
0
0
0
0
439
468
806
543
665
1,094
723
2,174
2,919
5,174
3,047
2,745
2,674
2,853
2,085
2,505
3,775
3,7752,5052,0852,8532,6742,7453,0475,1742,9192,1747231,0946655438064684390000
       Other Current Liabilities 
0
0
0
489
448
1,706
815
552
665
1,448
1,637
2,326,167
2,919
5,173,588
3,047
2,745
2,674
2,853
2,085
2
3,775
3,77522,0852,8532,6742,7453,0475,173,5882,9192,326,1671,6371,4486655528151,706448489000
   > Long-term Liabilities 
0
0
0
0
0
109
109
109
109
131
92
53
13
5,304
92
53
141
151
107
61
16
166110715114153925,30413539213110910910910900000
       Deferred Long Term Liability 
0
0
0
0
263
0
0
101
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000101002630000
> Total Stockholder Equity
0
0
0
943
536
23,228
21,570
19,699
81,732
79,613
75,729
71,571
65,315
61,076
59,025
56,038
52,575
48,259
45,412
40,908
35,765
35,76540,90845,41248,25952,57556,03859,02561,07665,31571,57175,72979,61381,73219,69921,57023,228536943000
   Common Stock
0
0
0
11
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1111111111111111011000
   Retained Earnings Total Equity000-47,897-43,151-39,28300000-17,429-15,112-12,6600000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-48
-103
-93
-311
-348
-435
-371
-300
-262
-139
-107
2
2-107-139-262-300-371-435-348-311-93-103-48000000000
   Capital Surplus 
0
0
0
0
7,765
0
0
32,358
96,843
97,088
0
0
0
0
0
95,691
96,025
96,417
0
0
0
00096,41796,02595,6910000097,08896,84332,358007,7650000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
7,670
7,765
31,290
31,333
32,358
96,843
97,088
97,313
96,686
94,770
95,060
95,361
95,691
96,025
96,417
96,608
96,259
96,447
96,44796,25996,60896,41796,02595,69195,36195,06094,77096,68697,31397,08896,84332,35831,33331,2907,7657,670000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-175
Gross Profit-175-175
 
Operating Income (+$)
Gross Profit-175
Operating Expense-17,703
Operating Income-17,878-17,878
 
Operating Expense (+$)
Research Development11,894
Selling General Administrative5,983
Selling And Marketing Expenses5,977,447
Operating Expense17,7035,995,324
 
Net Interest Income (+$)
Interest Income573
Interest Expense-0
Other Finance Cost-0
Net Interest Income573
 
Pretax Income (+$)
Operating Income-17,878
Net Interest Income573
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-15,962-19,794
EBIT - interestExpense = -17,878
-15,962
-15,962
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-17,878-15,962
Earnings Before Interest and Taxes (EBITDA)-17,703
 
After tax Income (+$)
Income Before Tax-15,962
Tax Provision-0
Net Income From Continuing Ops-15,157-15,962
Net Income-15,962
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses17,878
Total Other Income/Expenses Net1,916-573
 

Technical Analysis of Lantern Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lantern Pharma Inc. The general trend of Lantern Pharma Inc is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lantern Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lantern Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.8901 < 6.7958 < 7.21.

The bearish price targets are: 3.85 > 3.85 > 3.83.

Tweet this
Lantern Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lantern Pharma Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lantern Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lantern Pharma Inc. The current macd is -0.43526263.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lantern Pharma Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lantern Pharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lantern Pharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Lantern Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartLantern Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lantern Pharma Inc. The current adx is 24.06.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lantern Pharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Lantern Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lantern Pharma Inc. The current sar is 3.93302042.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Lantern Pharma Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lantern Pharma Inc. The current rsi is 36.13. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Lantern Pharma Inc Daily Relative Strength Index (RSI) ChartLantern Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lantern Pharma Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lantern Pharma Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Lantern Pharma Inc Daily Stochastic Oscillator ChartLantern Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lantern Pharma Inc. The current cci is -62.58684681.

Lantern Pharma Inc Daily Commodity Channel Index (CCI) ChartLantern Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lantern Pharma Inc. The current cmo is -29.72069142.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lantern Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartLantern Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lantern Pharma Inc. The current willr is -74.58563536.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Lantern Pharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Lantern Pharma Inc Daily Williams %R ChartLantern Pharma Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lantern Pharma Inc.

Lantern Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lantern Pharma Inc. The current atr is 0.42253629.

Lantern Pharma Inc Daily Average True Range (ATR) ChartLantern Pharma Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lantern Pharma Inc. The current obv is 2,474,175.

Lantern Pharma Inc Daily On-Balance Volume (OBV) ChartLantern Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lantern Pharma Inc. The current mfi is 21.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Lantern Pharma Inc Daily Money Flow Index (MFI) ChartLantern Pharma Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lantern Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Lantern Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lantern Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.130
Ma 20Greater thanMa 504.888
Ma 50Greater thanMa 1005.573
Ma 100Greater thanMa 2006.063
OpenGreater thanClose4.380
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lantern Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Lantern Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lantern Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lantern Pharma Inc

I send you an email if I find something interesting about Lantern Pharma Inc.


Stay informed about Lantern Pharma Inc.

Receive notifications about Lantern Pharma Inc in your mailbox!